Premature babies who were given monoclonal antibody palivizumab to protect against respiratory syncytial virus infection had 61% fewer days of wheezing in the first year of life than the placebo group, Dutch researchers found. They also noted a lower number of infants with recurrent wheeze in the palivizumab group. The study was published in the New England Journal of Medicine.
Palivizumab in preemies reduces wheezing, study finds
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|